For research use only.
CJC-1295
CJC-1295 is a lab-made version of GHRH, the brain’s "go" signal that tells the pituitary gland to release growth hormone.[1][2]
Pathway: GHRH. CJC-1295 is a lab-made version of the first 29 amino acids of natural GHRH, the brain’s "go" signal for growth hormone, with four amino acids swapped.[1][2]
With or without DAC: DAC is an add-on that makes CJC-1295 last much longer in the blood, so it’s taken less often.[1][2] The core peptide and its pathway are the same either way.[1]
Origin: Identified in 2005 by Jetté and colleagues at ConjuChem in Montreal as a long-lasting analog of human GRF(1-29) that sticks to albumin in the blood.[1]
Research areas
Human and animal studies have focused on how it raises the body’s own growth hormone signal.
Evidence level
Level 3 of 4: Small human trialsRandomized, placebo-controlled studies in healthy adults showed sustained GH and IGF-I increases with the long-acting (DAC) form.[2][3]
Why so few human trials?Cautions
Studies and regulators point to several reasons for care.
- FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and says available clinical data are limited[4]
- The published human studies tested the long-acting form with DAC, not a separate no-DAC product[2][3]
CJC-1295 is not FDA approved.[4]
CJC-1295 goes by several names.
- Long-acting GHRH analog[2][3]
- Modified GRF (1-29), a common market name for the core without DAC
- hGRF(1-29) analog with an albumin-binding group (the DAC form)[1]
Often stacked with
Ipamorelin. CJC-1295 and ipamorelin are paired because they flip two different switches for GH release, so one doesn’t just repeat the other.[1][5]
Storage basics General
These general basics apply to most freeze-dried research peptides.
Sources and studies
These studies and official pages are the research behind this profile.
- 1Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analogJetté L, et al. (2005) · Endocrinology
- 2Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsTeichman SL, et al. (2006) · The Journal of Clinical Endocrinology & Metabolism
- 3Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogIonescu M, Frohman LA (2006) · The Journal of Clinical Endocrinology & Metabolism
- 4Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration (2026)
- 5Ipamorelin, the first selective growth hormone secretagogueRaun K, et al. (1998) · European Journal of Endocrinology
- 6Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormoneBowers CY, et al. (1990) · The Journal of Clinical Endocrinology & Metabolism